|
Cellular Angiogenesis Assay |
|
The test model
Angiogenesis, the formation of new blood vessels from pre-existing ones, is a physiological process during growth and development. Beyond that, angiogenesis is mandatory for tumor progression and is involved in other pathological disorders (e.g. psoriasis, macular degeneration). ProQinase's cellular angiogenesis assay mimics the first steps of the in vivo situation in a cellular 3D test system. In this assay pro-angiogenic compounds/growth factors induce EC sprouting, whereas anti-angiogenic compounds inhibit growth factor induced EC sprouting.
In brief, the method can be described as follows: In a viscous medium endothelial cells (ECs) aggregate overnight to form a cellular spheroid. The formed human EC spheroids are embedded in a defined matrix (e.g. collagen or fibrin), stimulated (e.g. with VEGF-A or FGF-2) and finally EC sprouting is quantified. |
|
Assays offered at ProQinase for the analysis of
critical hallmarks of cancer growth
[click here to enlarge image]
|
|
Study example
The study example shows the result from testing of 40 compounds for their impact on VEGF-A induced angiogenic sprouting of human endothelial cells.
This primary screen was performed at a single concentration of 10 µM (the same 40 compounds were tested in parallel in the soft agar assay and the cell migration assay). The effect of the compounds on sprouting intensity was determined and scored as "no inhibitory effect" (labeled with 1) and "inhibitory effect" (labeled with 0). Five compounds showed inhibitory effects in this primary screen.
In the second part of the study the IC50 value was determined for compound 29 which showed activity in the primary screen. The inhibitory potency of the compound was confirmed with an IC50 value of 62nM. |
|
Primary screen of 40 compounds in the cellular
angiogenesis assay (test conc.: 10 µM)
[click here to enlarge image]
|
Our service
The assay system is suitable for anti-angiogenic lead identification and optimization. ProQinase offers single concentration testing (in duplicate) of anti-angiogenic compounds and standard IC50 determination of such compounds by testing at 7 concentrations in semi-log steps. Assays for potential pro-angiogenic compounds can be designed according to customers' need. The attractiveness of this test system for large scale screening is described in a poster, published 2007 at the AACR meeting.
| Cellular Angiogenesis Assay Services |
Price
(EUR) |
Price
(USD) |
|
Single concentration measurement of one test compound
(compounds tested in duplicate; for projects with at least 7 test compounds) |
250 |
325 |
IC50 determination of one test compound
(7 concentrations, singlicate, semi-log dilutions) |
800 |
1,040 |
| Project Setup Fee (setup, reference IC50 and report) |
2,100 |
2,730 |
|
|
